October 2018 Br J Cardiol 2018;25(suppl 3):S12–S19 doi:10.5837/bjc.2018.s14
Francisco Leyva
Professor Francisco Leyva Introduction Cardiac resynchronisation therapy (CRT) is a standard treatment for patients with heart failure (HF), impaired left ventricular (LV) function and a wide QRS complex. The therapy emerged following the recognition that disturbances in inter- and intra-ventricular conduction contribute to LV dysfunction. Since its first clinical use,1,2 robust evidence from randomised-controlled trials (RCTs) has supported its use in patients with severe and mild HF. In combination with defibrillation (CRT-D), CRT reduces mortality from pump failure and sudden, arrhythmic cardiac death (SCD). Since the last RCTs on CRT,3 th
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits